The aim of the study is to describe the real-world profile of patients treated with adalimumab FK in gastroenterology, dermatology or rheumatology in order to evaluate in this population the predictive factors of therapeutic response (in particular nutritional status) and generate hypothesis between nutritional status and therapeutic response.

Inclusion Criteria:

• Patients at least 18 years old who agree to participate in the study and do not object to the use of their health data
• A disorder treated with anti-TNF therapy
• Whose physician made the decision to initiate adalimumab treatment prior to the study

Exclusion Criteria:

• Patients participating in an interventional therapeutic trial at the time of inclusion
• Patients who are unwilling or unable to fulfil follow-up requirements (patients who cannot be reached by phone or complete the self-administered questionnaire or not fluent in French

Adults patients with rhumatologic, gastrologic or dermatologic disease eligible to a treatment with adalimumab